-
2024-519699-24-00
4
2026-04-23
IgA nephropathy
-
2025-522051-26-00
5
2026-04-23
Acquired Angioedema due to C1 Inhibitor Deficiency
-
2024-517943-29-00
5
2026-04-21
Pulmonary Hypertension associated with interstitial lung disease (WHO
-
2025-522145-21-00
5
2026-04-13
Metastatic hormone sensitive prostate cancer
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2024-519555-28-00
5
2026-03-18
Dravet syndrome
-
2025-522361-30-00
5
2026-03-17
Primary Mitochondrial Disease, Mitochondrial DNA 3243A>G variant and A
-
2025-521858-42-00
5
2026-03-16
Hemophilia
-
2025-522437-65-00
4
2026-03-06
small-cell lung cancer
-
2024-519579-24-00
5
2026-02-26
Classic Congenital Adrenal Hyperplasia
-
2025-522273-10-00
3
2026-02-24
Rheumatoid Arthritis
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-520766-22-00
5
2026-01-21
Myotonic Dystrophy Type 1
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2022-503140-41-00
5
2025-12-19
Melanoma
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2025-521299-76-00
7
2025-12-18
Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes wi
-
2024-519901-36-00
5
2025-12-17
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
-
2025-521276-59-00
5
2025-12-16
Autosomal dominant polycystic kidney disease (ADPKD)
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma